Article
Infectious Diseases
David Rial-Crestelo, Rosa de Miguel, Rocio Montejano, Lourdes Dominguez-Dominguez, Paula Aranguren-Rivas, Andres Esteban-Cantos, Otilia Bisbal, Mireia Santacreu-Guerrero, Monica Garcia-Alvarez, Belen Alejos, Asuncion Hernando, Laura Bermejo-Plaza, Julen Cadinanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, Jose Ramon Arribas
Summary: In the ART-PRO pilot trial, treatment with dolutegravir plus lamivudine maintained virological suppression at 96 weeks without any virological failures. Baseline proviral DNA sequencing revealed lamivudine resistance mutations in participants.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Medicine, General & Internal
Jesus Troya, Roberto Pedrero-Tome, Luis Buzon, Carlos Duenas
Summary: This study investigated the immune recovery in people living with HIV receiving antiretroviral treatment. The research found that late HIV diagnosis, AIDS stage, and age over 50 years were the main predictors of immunological failure. Conversely, starting with a normalized immune status was associated with a higher chance of successful treatment with DTG plus 3TC.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Infectious Diseases
Yu-Lin Lee, Kuan-Yin Lin, Shu-Hsing Cheng, Po-Liang Lu, Ning-Chi Wang, Mao-Wang Ho, Chia-Jui Yang, Bo-Huang Liou, Hung-Jen Tang, Shie-Shian Huang, Sung-Hsi Huang, Tun-Chieh Chen, Chi-Ying Lin, Shih-Ping Lin, Yuan-Ti Lee, Chien-Ching Hung
Summary: This retrospective study included 77 patients receiving dolutegravir plus boosted protease inhibitor treatment at 15 designated hospitals for HIV care in Taiwan. The study found that the two-drug regimen containing dolutegravir plus boosted protease inhibitor was effective for highly experienced HIV-positive patients. Virological response rate reached 85.7% at Week 48, but metabolic impact and weight gain should be closely monitored.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Virology
Carmen Hidalgo-Tenorio, Juan Pasquau, David Vinuesa, Sergio Ferra, Alberto Terron, Isabel SanJoaquin, Antoni Payeras, Onofre Juan Martinez, Miguel Angel Lopez-Ruz, Mohamed Omar, Javier de la Torre-Lima, Ana Lopez-Lirola, Jesus Palomares, Jose Ramon Blanco, Marta Montero, Coral Garcia-Vallecillos
Summary: Real-world data demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory for treatment-naive HIV-1 patients. It can control viral load and increase CD4 cell count. Additionally, this regimen can moderately increase weight and abdominal circumference in patients.
Article
Infectious Diseases
Colin Deschanvres, Jacques Reynes, Isabelle Lamaury, David Rey, Romain Palich, Firouze Bani-Sadr, Olivier Robineau, Claudine Duvivier, Laurent Hocqueloux, Lise Cuzin, Veronique Joly, Francois Raffil, Andre Cabie, Clotilde Allavena
Summary: Maintenance ART with dolutegravir-based dual regimens has shown efficacy in HIV-1infected subjects, but real-life data are limited. In this study, virological failure and resistance-associated mutations were assessed in dolutegravir maintenance regimens. Results indicated that careful virological screening is essential before switching to dolutegravir maintenance regimens in virologically suppressed patients.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Immunology
Javier Martinez-Sanz, Raquel Ron, Elena Moreno, Matilde Sanchez-Conde, Alfonso Muriel, Luis Fernando Lopez Cortes, Jose Ramon Blanco, Juan Antonio Pineda, Alvaro Mena, Sonia Calzado Isbert, Santiago Moreno, Sergio Serrano-Villar
Summary: This study compared the impact of a 2-drug regimen with dolutegravir plus lamivudine to a 3-drug regimen based on other integrase strand transfer inhibitors (INSTIs) on the recovery of the CD4/CD8 ratio in people with HIV. The results showed no difference in the normalization rates of the CD4/CD8 ratio at 48 weeks between the two treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Juan M. Tiraboschi, Jhon Rojas, Henrik Zetterberg, Kaj Blennow, Jordi Niubo, Johanna Gostner, Antonio Navarro-Alcaraz, Camila Piatti, Dietmar Fuchs, Magnus Gisslen, Raul Rigo-Bonnin, Esteban Martinez, Daniel Podzamczer
Summary: The study suggests that the use of dolutegravir and lamivudine dual therapy can maintain viral control in cerebrospinal fluid without increasing markers of inflammation or neuronal injury. The levels of dolutegravir in the cerebrospinal fluid were within an effective range for maintaining viral suppression.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Pascale Perfezou, Nolwenn Hall, Jean-Charles Duthe, Basma Abdi, Sophie Seang, Cedric Arvieux, Isabelle Lamaury, Amelie Menard, Anne-Genevieve Marcelin, Christine Katlama, Romain Palich
Summary: This study reports the experience of using doravirine/lamivudine as maintenance therapy in HIV patients. The results showed that this treatment regimen can effectively suppress viral replication and improve CD4+ T cell count.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Lisi Deng, Chunna Li, Ping Chen, Xiaoqing Luo, Xinchun Zheng, Lanlan Zhou, Yi Zhou, Jinyu Xia, Zhongsi Hong
Summary: This study evaluated the efficacy and safety of dolutegravir plus lamivudine in ART-naive adults in China. The results showed that DTG + 3TC achieved virologic suppression more rapidly than EFV + TDF + 3TC after 12 and 24 weeks, and there were also significant changes in CD4 cell counts.
BMC INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Jin Li, Dabiao Chen, Zhiwei Wen, Yanzhang Du, Zhanlian Huang, Huijun Zhong, Yanhao Wang, Sichun Yin
Summary: This study evaluated the real-world efficacy and safety of DTG + 3TC in ART-naive HIV-1-infected adults in China. The results showed that DTG + 3TC achieved virological suppression more rapidly and stably, with better immunological response and less adverse drug effects.
Article
Immunology
Rosa De Miguel Buckley, David Rial-Crestelo, Rocio Montejano, Adriana Pinto, Maria Jimenez-Gonzalez, Maria Lagarde, Andres Esteban-Cantos, Paula Aranguren-Rivas, Julen Cadinanos, Otilia Bisbal, Juan Miguel Castro, Mireia Santacreu-Guerrero, Laura Bermejo-Plaza, Victoria Moreno, Asuncion Hernando, Luz Martin-Carbonero, Rafael Rubio, Rafael Delgado, Jose Ramon Arribas, Federico Pulido
Summary: In this pilot clinical trial, rates of residual replication in individuals without lamivudine resistance-associated mutations were evaluated after switching to dolutegravir plus lamivudine. The results showed no changes in residual viremia based on qualitative detection methods, regardless of past lamivudine resistance.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Franco Maggiolo, Roberto Gulminetti, Layla Pagnucco, Margherita Digaetano, Adriana Cervo, Daniela Valenti, Annapaola Callegaro, Cristina Mussini
Summary: The long-term results of using the combination of dolutegravir and lamivudine show good efficacy and tolerability, with no virologic failure and positive impact on CD4 cell count and CD4/CD8 ratio.
BMC INFECTIOUS DISEASES
(2022)
Review
Infectious Diseases
Rickesh Patel, Lee Evitt, Ilias Mariolis, Simona Di Giambenedetto, Antonella D'Arminio Monforte, Jose Casado, Alfonso Cabello Ubeda, Laurent Hocqueloux, Clotilde Allavena, Tristan Barber, Diwakar Jha, Rahul Kumar, Rahul Dinesh Kamath, Tia Vincent, Jean van Wyk, Justin Koteff
Summary: The two-drug regimen of dolutegravir plus lamivudine has shown durable efficacy for up to 3 years in phase III studies, demonstrating a high barrier to resistance in HIV patients. A systematic literature review of real-world evidence confirms high rates of virologic response and low rates of discontinuation in clinical practice, consistent with randomized controlled trial data.
INFECTIOUS DISEASES AND THERAPY
(2021)
Article
Infectious Diseases
Xiaoyan Yang, Yanhua Fu, Xiaoxin Xie, Lin Gan, Chunli Song, Yebing Song, Jun Li, Hai Long
Summary: The study found that the two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) was effective in achieving viral suppression in both ART-naive and ART-experienced individuals living with HIV in Southwestern China. The CD4 count also significantly increased in both groups. Importantly, there were no discontinuations of DTG+3TC due to adverse events within the 48-week study period, indicating a low prevalence of drug-related side effects.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2022)
Article
Infectious Diseases
Abraham Saborido-Alconchel, Ana Serna-Gallego, Luis E. Lopez-Cortes, Maria Trujillo-Rodriguez, Juan Manuel Praena-Fernandez, Montserrat Dominguez-Macias, Carmen Lozano, Esperanza Munoz-Muela, Nuria Espinosa, Cristina Roca-Oporto, Cesar Sotomayor, Marta Herrero, Alicia Gutierrez-Valencia, Luis F. Lopez-Cortes
Summary: This substudy compared the activity of dolutegravir/lamivudine with dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC) in the male genital tract. The study found no significant difference in the percentage of undetectable seminal plasma HIV-1-RNA after 12 weeks of treatment between the two groups of treatment-naive individuals living with HIV.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Biochemical Research Methods
Marine Perrier, Nathalie Desire, Claire Deback, Henri Agut, David Boutolleau, Sonia Burrel
JOURNAL OF VIROLOGICAL METHODS
(2016)
Letter
Infectious Diseases
Marine Perrier, Melanie Bertine, Quentin Le Hingrat, Veronique Joly, Benoit Visseaux, Gilles Collin, Roland Landman, Yazdan Yazdanpanah, Diane Descamps, Charlotte Charpentier
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2017)
Article
Infectious Diseases
Marine Perrier, Charlotte Charpentier, Gilles Peytavin, Minh Le, Louis Blondel, Benoit Visseaux, Veronique Joly, Adriana Pinto, Sophie Matheron, Yazdan Yazdanpanah, Diane Descamps, Roland Landman
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2017)
Article
Infectious Diseases
Marine Perrier, Benoit Visseaux, Roland Landman, Veronique Joly, Eve Todesco, Yazdan Yazdanpanah, Vincent Calvez, Anne-Genevieve Marcelin, Diane Descamps, Charlotte Charpentier
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2018)
Article
Infectious Diseases
Charlotte Charpentier, Gilles Peytavin, Minh P. Le, Veronique Joly, Ornella Cabras, Marine Perrier, Sylvie Le Gac, Bao Phung, Yazdan Yazdanpanah, Diane Descamps, Roland Landman
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2018)